The Yme1l1 Knockout HL-1 Cell Line is a CRISPR/Cas9-edited mouse cardiac muscle cell line engineered to disrupt the Yme1l1 gene, which encodes a mitochondrial inner membrane i-AAA protease. This targeted-gene disruption model is provided as an established, ready-to-use knockout cell line derived from the HL-1 atrial cardiomyocyte lineage, offering a robust in vitro system for investigating mitochondrial proteostasis and dynamics in a physiologically relevant cardiac context. The cell line is generated using CRISPR/Cas9-mediated gene disruption, resulting in a loss-of-function model that enables precise dissection of YME1L1-dependent processes without relying on pharmacological inhibition or transient knockdown approaches.
The HL-1 host cell line originates from the AT-1 mouse atrial cardiomyocyte tumor lineage and retains a highly differentiated, spontaneously contracting phenotype. These cells maintain hallmark cardiac features, including expression of cardiac-specific markers, organized sarcomeric structures, and the ability to generate rhythmic action potentials. Their continuous proliferation capacity, coupled with retained atrial cardiomyocyte characteristics, makes HL-1 cells a widely accepted model for long-term studies of cardiac cell biology, electrophysiology, and mitochondrial function, circumventing the limitations of primary cardiomyocyte cultures.
YME1L1 functions as a quality control protease within the mitochondrial inner membrane, where it degrades misfolded and damaged proteins to maintain proteostasis, and catalyzes the regulated processing of OPA1, a dynamin-like GTPase essential for mitochondrial inner membrane fusion. YME1L1 operates in concert with AFG3L2, forming the heterooligomeric i-AAA complex, and counterbalances the stress-activated protease OMA1. Upstream signals such as mitochondrial membrane potential and unfolded protein stress, mediated by transcription factors including ATF5 and CHOP, modulate YME1L1 expression. Key downstream targets include cleaved OPA1 isoforms, respiratory chain subunits like NDUFA9, and the lipid transfer protein PRELID1. This signaling node integrates mitochondrial proteotoxic stress responses, cristae remodeling, and fusion/fission dynamics, with additional interplay among STOML2, MFN1/2, and DRP1.
In the context of HL-1 cells, YME1L1 ablation profoundly disrupts mitochondrial morphology and bioenergetics, recapitulating features of cardiomyopathies and mitochondrial disorders. The spontaneous contractile activity of HL-1 cells imposes a high energy demand, making them exquisitely sensitive to perturbations in oxidative phosphorylation and mitochondrial quality control. YME1L1 loss leads to unopposed OPA1 processing by OMA1, aberrant cristae architecture, and compromised respiratory chain assembly, providing a direct link between mitochondrial proteostasis and cardiac contractile dysfunction. This model thus offers a tractable platform to explore mechanistic underpinnings of atrial myopathies, ischemia-reperfusion injury, and inherited mitochondrial diseases within a beating-cell environment.
Researchers can employ this knockout cell line to interrogate mitochondrial dynamics, proteotoxic stress pathways, and metabolic dysfunction in cardiovascular research. Representative applications include assessing OPA1 cleavage patterns via western blotting, visualizing mitochondrial networks with confocal microscopy, measuring ATP synthesis rates, and performing Seahorse respirometry for real-time bioenergetic profiling. Additional assays such as blue native PAGE for respiratory supercomplex integrity, co-immunoprecipitation of YME1L1-AFG3L2 interactions, and apoptosis detection through cytochrome c release or TUNEL staining are readily compatible. The model is also suited for high-content screening of small molecules targeting mitochondrial quality control and for dissecting signaling cascades in cardiac ischemia-reperfusion injury. For additional information, contact Ascent Research.
